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Regulatory T cells (T reg cells) are a subpopu-
lation of CD4+ T cells that are hyporesponsive 
to antigenic stimulation, but exert immunosup-
pressive eff  ects to control the immune response 
(1). Several types of T reg cells can be identi-
fi  ed based on cell surface markers or cytokine 
secretion. T reg cells develop in the thymus and 
express cell surface molecules, including the 
IL-2 receptor α chain (IL-2Rα), cytotoxic T-
lymphocyte antigen-4, glucocorticoid-induced 
tumor necrosis factor receptor family–related 
gene, and lymphocyte activation antigen-3. Defi  -
ciency or dysfunction of T reg cells can augment 
tumor immunity, but predispose to autoimmu-
nity; in contrast, an expansion of these cells can 
promote tolerance of transplanted tissues (1).
FoxP3 is expressed exclusively in T reg cells 
and regulates their development in the thymus 
and maintenance in the periphery (2). FoxP3 
is mutated in the Scurfy mutant mouse and in 
patients with IPEX (immune dysregulation, 
polyendocrino pathy, enteropathy, X-linked) 
syndrome (3). FoxP3 belongs to the forkhead 
actor family, containing a highly conserved, C-
terminal winged-helix/forkhead, DNA-binding 
domain, a C2H2 zinc fi  nger, and a leucine zip-
per (3). The N-terminal domain of FoxP3 is 
unique to the FOXP subfamily, and it is critical 
for transcriptional repression (3). FoxP3 can in-
teract with NF-AT and NF-κB to repress cy-
tokine gene expression (4, 5).
In the thymus, intermediate affi   nity inter-
actions between the TCR and MHC induce 
FoxP3 expression and promote the develop-
ment of T reg cells (6). T reg cells can also be 
generated in the periphery in the context of 
suboptimal TCR stimulation (7). Production of 
human thymic stromal lymphopoietin, which 
is an IL-7–like cytokine that signals via thymic 
stromal-derived lymphopoietin receptor and 
IL-7Rα (8), by Hassall’s corpuscles was reported 
to promote the generation of thymic T reg 
cells by activating dendritic cells (9). Mice lack-
ing CD28 or its ligands, CD80 and CD86, 
have diminished T reg cells, suggesting a role 
for these accessory molecules in thymic selection 
of T reg cells and the maintenance of the periph-
eral T reg cell compartment (10). Nevertheless, 
the T reg cells seen in the absence of CD28 
have normal levels of IL-2Rα and FoxP3 (11); 
thus, FoxP3 expression is not absolutely depen-
dent on the CD28 pathway. IL-2 is important 
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for T reg cell development, as shown by diminished FoxP3+ 
T reg cells in the thymus and peripheral lymphoid organs in 
Il2 (12), Il2ra (12), or Il2rb (13) knockout mice. Both IL-2 
and transforming growth factor (TGF)-β can induce the 
conversion of CD4+CD25– into CD4+CD25+ T cells with 
elevated FoxP3 expression in vitro (14), which is consistent 
with the presence of both IL-2 and TGF-β response ele-
ments in the Il2ra gene (15–17).
Studies of FoxP3 regulation have revealed a proximal 5′ 
regulatory region that was reported to contribute to TCR-
mediated regulation of the gene (18), whereas IL-2–induced 
FoxP3 expression has been attributed to intronic tandem 
GAS motifs that bind Stat5 in vitro (19). We now identify a 
potent new TCR response element in the FoxP3 gene and 
demonstrate DNA methylation-dependent control of FoxP3 
gene expression.
RESULTS AND D  I  S  C  U  S  S  I  O  N 
Identifi  cation of an enhancer-like TCR-response element 
in the FoxP3 gene
To delineate critical regulatory elements controlling FoxP3 
gene expression, we used comparative genomics to identify 
conserved noncoding sequences (CNSs). Consistent with pre-
vious observations (18, 19), using the VISTA computer pro-
gram, we identifi  ed three CNSs with >75% sequence identity 
between humans and mice. CNS1 is in the promoter region, 
whereas CNS2 and CNS3 are in the fi  rst intron (Fig. 1 A). The 
promoter region (CNS1; −500 to 100 region) was cloned 5′ 
to the luciferase reporter gene in pGL3-Basic and transfected 
into Jurkat T cells. It exhibited an approximately fourfold 
increase in activity in response to PMA + ionomycin (Fig. 1 A). 
When CNS2 was cloned upstream of CNS1, only a modest 
increase was observed, but CNS3 induced a 20-fold increase 
in activity, which is indicative of a potent enhancer (Fig. 1 A). 
When the same constructs were transfected into primary splenic 
T cells, followed by activation with anti-CD3 + anti-CD28, 
activity was lower than in Jurkat T cells, but the CNS3 region 
again exhibited enhancer-like activity (Fig. 1 A) that we delin-
eated to the +4,301 to +4,500 region (bottom construct), with 
5′ truncation to +4,351 (fourth construct) or 3′ truncation 
to +4,450 (seventh construct) signifi  cantly lowering activ-
ity (Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20070109/DC1). These results underscore the potency 
of CNS3.
CREB/ATF is important for the activity of the TCR 
response element
The sequences of the FoxP3 promoter and intronic regions are 
shown in Fig. S2 (A and B, respectively; available at http://www
.jem.org/cgi/content/full/jem.20070109/DC1). The pro-
moter region contains sequence motifs that resemble NF-AT 
and AP-1 motifs and a GC box (Fig. S2 A) (18). The intronic 
region contains two GAS motifs (19); additionally, we iden-
tifi  ed a TGACGTCA putative cyclic-AMP response element 
binding protein (CREB)/activating transcription   factor (ATF) 
motif with an overlapping YY1 motif (Fig. S2 B).
CREB and a family of ATFs are transcriptional activators 
(20), so we investigated if the putative FoxP3 CREB/ATF 
site is important for the activity of the intronic TCR response 
element. We evaluated CREB binding to this motif using 
electrophoretic mobility shift assays (EMSAs), with DNA 
probes spanning the CREB site at +4,470 (Fig. S3, available 
at http://www.jem.org/cgi/content/full/jem.20070109/DC1). 
For these studies, we used nuclear extracts from primary 
mouse splenic CD4+ T cells expanded with anti-CD3, 
anti-CD28, and IL-2 for 6 d. EMSAs revealed four com-
plexes (denoted I, II, III, and IV; Fig. 1 B, lane 1) whose 
formation was inhibited by excess unlabeled probe (lanes 2 
and 3). In contrast, an oligonucleotide containing a mutant 
CREB site (mtCREB-1) had little eff  ect on the formation 
of complexes II and III, but still inhibited complex I (Fig. 
1 B, lanes 4 and 5). Consistent with this, the formation of 
complexes II and III, but not of complex I, was inhibited by 
a consensus CREB binding site oligonucleotide (Fig. 1 B, 
lanes 6 and 7), whereas an oligonucleotide with a mutant 
CREB site (mtCREB-2) did not inhibit formation of any 
of the complexes (lanes 8 and 9). When EMSAs were per-
formed with the mtCREB-1 probe, complexes II and III 
were not detected (Fig. 1 B, lane 10), and only complexes 
II and III were detected with a probe containing a consensus 
CREB binding site but lacking relevant surrounding sequences 
(lane 11). Similar CREB binding activity was observed using 
nuclear extracts from CD4+CD25+ natural T reg cells (Fig. 1 C, 
lanes 3 and 4 vs. 1 and 2). Antibodies specifi  c for CREB or 
phospho-CREB supershifted complex II (Fig. 1 D), confi  rm-
ing CREB binding; because of the position of the supershifted 
band, the eff  ect of the antibody on complex III could not be 
determined. ATF1 and ATF2 have similar binding specifi  city 
to CREB (20), and like CREB, both ATF1 and ATF2 also 
bind to a WT, but not mutant, probe (Fig. 1 E).
We next investigated the functional signifi  cance of the 
CREB/ATF sites. Mutation of the CREB site in the +4,301 
to +4,500 TCR response element greatly decreased activity 
(Fig. 1 F). Moreover, cotransfection of 0.5 or 5 μg of a domi-
nant-negative CREB construct (denoted “ACREB”) that can 
inhibit not only CREB but also ATF1 and ATF2 (21) dimin-
ished PI inducibility of the CNS3-containing construct in a 
dose-responsive fashion, whereas the empty ex  pression vector 
had no eff  ect (Fig. 1 G, bottom). To confi  rm the importance 
of CREB/ATF, we examined the ability of an ACREB-ex-
pressing lentivirus to lower FoxP3 expression in HLTV-I 
transformed MT-2 cells, which constitutively express FoxP3 
(22). Compared with a control “empty” virus, the ACREB-
expressing virus signifi  cantly decreased FoxP3 expression, but 
not IL-2Rα expression, which was used as an internal control 
(Fig. 1 H). We also observed that complex I contains YY1 
(Fig. S4, available at http://www.jem.org/cgi/content/full/
jem.20070109/DC1); however, mutation of the YY1 site did 
not aff  ect activity, and knocking down YY1 expression with 
a shRNA construct also did not decrease FoxP3 expression 
(unpublished data). Thus, CREB/ATF, but not YY1, is a 
critical component of the TCR response element.JEM VOL. 204, July 9, 2007  1545
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Inverse correlation of FoxP3 expression and methylation 
of the intronic CpG island
Because of the lineage- and tissue-specifi  c expression of the 
FoxP3 gene and because CREB binding can be inhibited by 
CpG methylation (23), we hypothesized that DNA methyla-
tion might be an important control mechanism for FoxP3 
expression. Strikingly, analysis of the FoxP3 genomic locus with 
the MethPrimer computer program (24) revealed a single 
putative CpG island in the +4,393 to +4,506 region (Fig. 2 A) 
of CNS3. To evaluate the methylation status of CpG sequences 
in the promoter and CNS3 regions, we isolated FoxP3–
CD4+CD25– naive splenic T cells and FoxP3+CD4+CD25+ 
regulatory T cells (Fig. 2 B). For the −250 to +1 promoter 
region, we sequenced the sense strand of ≥20 individual 
Figure 1.  Identifi  cation of a TCR response element in the FoxP3 
gene. (A) A TCR-responsive enhancer in the CNS3 intronic region of the 
FoxP3 gene. Conserved noncoding regions are shown in the promoter 
and fi  rst intron regions. Jurkat cells were transfected with the indicated 
constructs. Transfected cells were either untreated or treated with PMA/
ionomycin for 17 h. Results are representative of three or more independent 
experiments (shown as the mean ± the SD). (B and C) EMSAs with the 
indicated probes; competitor oligonucleotides were added where indicated. 
In B, nuclear extracts were obtained from anti-CD3/anti-CD28–acti-
vated mouse CD4+ splenic T cells. In C, nuclear extracts were obtained 
from either CD4+CD25– splenic T cells (lanes 1 and 2) or from natural 
CD4+CD25+ T reg cells (lanes 3 and 4). (D) EMSA in the presence of 
specifi  c antibody using WT probes and nuclear extracts from anti-CD3/anti-
CD28–activated mouse CD4+ splenic T cells. (E) DNA affi  nity purifi  cation, 
followed by Western blotting for phospho-CREB, CREB, ATF-1, and ATF-2. 
Nuclear extracts were from human Kit225 cells stimulated with PMA + 
ionomycin. (F) The CREB binding site in CNS3 is essential for PI-induced 
FoxP3 promoter activity. A mutation in the CREB binding site was intro-
duced into FoxP3 reporter construct. Constructs were transfected into 
Jurkat cells, followed by no stimulation or stimulation with PI for 17 h. 
(G) Jurkat cells were transfected with the FoxP3 reporter construct plus 
either empty vector or 0.5 or 5 μg of the ACREB vector. Transfected cells 
were either untreated or treated with PMA/ionomycin for 17 h. (H) MT-2 cells 
were infected with the indicated lentiviruses, and puromycin-resistant 
cells were selected. Real-time PCR was used to analyze FoxP3 and IL-2Rα 
mRNA levels and normalized to the mRNA level of GAPDH. Results in F–H 
are representative of three or more independent experiments (shown as 
the mean ± the SD).1546  CREB/ATF-DEPENDENT FOXP3 GENE EXPRESSION | Kim and Leonard 
DNA clones and found that in male mice 10–45% of the CpG 
sites were methylated in CD4+CD25– cells, whereas none 
were methylated in CD4+CD25+ T reg cells (Fig. 2 C and 
Fig. S5 A, available at http://www.jem.org/cgi/content/full/
jem.20070109/DC1). Thus, even though the FoxP3 gene is 
not expressed in CD4+CD25– cells, less than half of the CpG 
sites in the promoter region were methylated in these cells. We 
also analyzed the CpG sites in the +4,201 to +4,500 intronic 
CpG island. In CD4+CD25+ T reg cells from male mice, al-
most no methylation of these sites was found, similar to the 
promoter region, but in CD4+CD25– T cells, the intronic 
CpG sites were almost completely methylated (Fig. 2 D and 
Fig. S5 B), suggesting that methylation of sites in the CpG is-
land inhibits FoxP3 expression in CD4+CD25– T cells.
We also examined the DNA methylation status of the 
FoxP3 promoter and CpG island regions in female mice (Fig. 
2, E and F; and Fig. S5, A and B). In the promoter region, 
female mice exhibited greater methylation in CD4+CD25– 
T cells and  50% methylation in CD4+CD25+ T reg cells 
(Fig. 2 E). In the intronic CpG island, they exhibited essen-
tially complete methylation in the CD4+CD25– T cells, but 
only 45–68% methylation in the CD4+CD25+ T reg cells (Fig. 
2 F). Because the FoxP3 gene is located on chromosome X, the 
diff  erence in methylation of the intronic CpG island region 
in male versus female T reg cells may result from the methyla-
tion status of the inactivated X chromosome. Thus, FoxP3 
expression inversely correlates with the methylation status of 
the intronic CpG island.
Like the splenic T reg cells, thymic CD4+CD25+ T reg 
cells from C57BL/6 mice exhibited little methylation in the 
promoter region (Fig. S6 A, far right, available at http://
www.jem.org/cgi/content/full/jem.20070109/DC1) and 
 70% demethylation in the intronic CpG island region (Fig. 
S6 B, far right). However, cell populations that do not ex-
press FoxP3, including CD4–CD8– DN, CD4+CD8+ DP, 
CD4+CD8–CD25–, and CD4–CD8+CD25– SP thymocytes, 
had almost complete methylation of the intronic CpG island 
(Fig. S6, B [fi  rst 4 panels] and C), even though they were 
only partially methylated in the promoter region, further in-
versely correlating FoxP3 expression and methylation of the 
intronic CpG island.
To determine if the demethylated status in T reg cells was 
specifi  c for the FoxP3 gene or a more general phenomenon, 
we examined the methylation status of the genes encoding IL-2 
and IFN-γ (Fig. S7, A and B, available at http://www.jem
.org/cgi/content/full/jem.20070109/DC1), focusing on sites 
whose methylation is known to be important for the regulation 
of these genes, either before versus after T cell activation (for 
the Il2 gene) (25, 26) or in Th1 versus Th2 cells (for the Ifng 
gene) (27). Unlike FoxP3, neither of these genes is expressed in 
T reg cells. The methylation status for the 5′ regulatory regions 
for both genes was similar in CD4+CD25– or CD4+CD25+ 
Figure 2.  DNA methylation status of CpG sites in the promoter 
and intronic CpG island region of the FoxP3 gene. (A) Identifi  cation 
of a CpG island in the fi  rst intron that corresponds to the TCR response 
element that binds CREB. (B) Expression of FoxP3 in CD4+CD25– versus 
CD4+CD25+ cells. (C–F) The DNA methylation status for these regions was 
determined from male (C and D) or female (E and F) C57BL/6 mice by 
bisulfi  te sequencing analysis. Each line represents one DNA strand; open 
circle, unmethylated CpGs; fi  lled circle, methylated CpGs.JEM VOL. 204, July 9, 2007  1547
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cell populations (Fig. S7, A–C), which is consistent with nei-
ther Il2 nor Ifng genes being expressed in the cell popula-
tions, thus further supporting the specifi  city of our fi  ndings 
for the diff  erential methylation of the FoxP3 gene in these 
two populations.
TGF-β–induced FoxP3 expression correlated 
with hypomethylation of the CpG intronic island
In addition to naturally occurring thymus-derived T reg cells, 
TGF-β can induce FoxP3 expression in splenic CD4+CD25– 
T cells and their diff  erentiation into T reg cells. We thus inves-
tigated the eff  ect of TGF-β on methylation of the FoxP3 
locus. Naive CD4+CD25– splenic T cells from male C57BL/6 
mice were purifi  ed by fl  uorescence-activated cell sorting, ac-
tivated with anti-CD3 + anti-CD28, and expanded with 
100 U/ml IL-2. FoxP3 expression was induced by treatment 
with TGF-β (Fig. 3 A). After 6 d in culture, the methyla-
tion status was assayed. In CD4+CD25– T cells not treated 
with TGF-β, which do not express FoxP3, the promoter 
region was more methylated than in naive CD4+CD25– 
T cells (see the CpG sites at −71, −62, −53, and −50; Fig. 
3 B, left, vs. Fig. 2 C, left). When the cells were cultured with 
TGF-β, which induces FoxP3 expression, the promoter region 
was less methylated than in naive CD4+CD25– cells (Fig. 3 B, 
right, vs. Fig. 2 C, left). The intronic CpG island remained 
fully methylated in the absence of TGF-β (Fig. 3 C, left, vs. 
Fig. 2 D, left), but the CpG sites at +4,275, +4,311, +4,361, 
+4,461, and +4,473 exhibited partial demethylation after treat-
ment with TGF-β (Fig. 3 C, right). Thus, TGF-β induced partial 
demethylation at the promoter and intronic CpG island, cor-
relating with increased FoxP3 expression (Fig. S8 A, available 
at http://www.jem.org/cgi/content/full/jem.20070109/DC1).
Treatment with 5-azacytidine induces FoxP3 expression
To further test whether DNA methylation repressed FoxP3 
expression, we used 5-azacytidine, which is a cytosine nucle-
oside analogue that inhibits DNA methyltransferase and which 
was previously shown to augment FoxP3 expression in 
human NK cells (19). CD4+CD25– cells were stimulated 
with anti-CD3 + anti-CD28 and IL-2 for 6 d. When cells 
were treated with 5-azacytidine from day 4 to 6, FoxP3 ex-
pression increased (Fig. 3 D), and DNA methylation in the 
promoter (Fig. 3 E) and intronic CpG island (Fig. 3 F) signif-
icantly decreased (Fig. S8 B), supporting the hypothesis that 
DNA methylation prevents FoxP3 expression in non–FoxP3-
producing CD4+CD25– T cells. A similar trend in methyla-
tion was seen after treatment with TGF-β (Fig. 3, A–C) or 
5-azacytidine (Fig. 3, D–F).
We also studied the eff  ect of 5-azacytidine in mouse 
cytotoxic CTLL-2 CD8+ T cells. 5-azacytidine markedly 
increased FoxP3 expression (Fig. S9 A, available at http://
www.jem.org/cgi/content/full/jem.20070109/DC1), and 
Figure 3.  Expression of the FoxP3 gene in TGF-β–stimulated 
T reg cells correlates with DNA demethylation, and treatment with 
5-azacytidine stimulates FoxP3 expression in non–T reg cells. 
(A–C) CD4+CD25– cells from male C57BL/6 mice isolated by FACS sorting 
were stimulated with 5 μg/ml of plate-bound anti-CD3 + 0.5 μg/ml anti-
CD28 + 100 U/ml IL-2 in the absence or presence of 5 ng/ml TGF-β for 
6 d. (A) The cells were stained with APC-CD4, PerCP-Cy5.5-CD25, and PE-
FoxP3. Graphs are shown for FoxP3 expression, gated for live cells. (B and C) 
The methylation status of CpG sites in the promoter region (B) or the 
intronic CpG island region (C) was determined by bisulfi  te sequencing 
analysis. (D–F) CD4+CD25– cells from male C57BL/6 mice were isolated by 
FACS sorting and stimulated with 5 μg/ml anti-CD3, 0.5 μg/ml anti-
CD28, and 100 U/ml IL-2 for 6 d, and 5-azacytidine was added for days 
4–6. (D) The cells were stained with APC-CD4, PerCP-Cy5.5-CD25, and 
PE-FoxP3. Graphs are shown for FoxP3 expression, gated for live cells. 
(E and F) The methylation status of CpG sites in the promoter region (E) or 
the intronic CpG island region (F) was determined by bisulfi  te sequencing 
analysis. Each line represents a DNA strand; open circle, unmethylated 
CpGs; fi  lled circle, methylated CpGs.1548  CREB/ATF-DEPENDENT FOXP3 GENE EXPRESSION | Kim and Leonard 
the promoter and intronic CpG island region, which were 
highly methylated in the untreated cells, became substantially 
less methylated (Fig. S9, B–D), again, correlating hypometh-
ylation with FoxP3 expression, even in a CD8+ cytotoxic T 
cell line where FoxP3 is not normally expressed.
Decreasing Dnmt1 induces FoxP3 expression
The major DNA methyltransferase responsible for maintain-
ing DNA methylation is Dnmt1 (28). We further assessed the 
role of DNA methylation for FoxP3 gene expression in vivo 
by using a lentiviral vector and RNA interference to decrease 
Dnmt1 expression. CTLL-2 cells that were GFP+ (indicative 
of successful viral transduction) were sorted by FACS. The 
expression of Dnmt1 mRNA (Fig. 4 A) and protein (Fig. 
4 B) was markedly decreased in CTLL-2 cells infected 
with lentivirus containing shRNA against Dnmt1, whereas 
Dnmt3a mRNA was unaff  ected (Fig. 4 A). Strikingly, FoxP3 
mRNA (Fig. 4 C) and protein (Fig. 4 D) were increased in 
Dnmt1-diminished cells within 4 d after infection, with 15–
20% of GFP-positive cells expressing FoxP3 by day 7 (Fig. 4 D), 
indicating an essential role for Dnmt1 in repressing FoxP3 
gene expression.
Figure 4.  Knockdown of Dnmt1 induces FoxP3 expression. 
(A–D) CTLL-2 cells were infected with the indicated lentiviruses, and GFP-
positive cells were sorted. (A) Real-time PCR was performed to analyze the 
mRNA levels of Dnmt1 and Dnmt3a and normalized with the 18S rRNA 
level. (B) Whole-cell lysates were separated with SDS-PAGE and were 
subjected to Western blotting using antibodies to Dnmt1 and actin. 
(C) Real-time PCR was performed to analyze the mRNA levels of FoxP3 
expression and normalized with the 18S rRNA level. Results in A and C are 
representative of at least three independent experiments (shown as the 
mean ± the SD). (D) Dot plot showing the expression of FoxP3 in CTLL-2 
cells infected with the indicated lentiviruses. (E–G) Essential role of CREB 
and its methylation for FoxP3 expression. (E) Inhibition of the FoxP3 
promoter activity by methylation at CpG sites in the intronic CpG island. 
Jurkat cells were transfected with the indicated constructs. Transfected 
cells were either untreated or treated with PMA/ionomycin for 17 h. 
Results in E are representative experiments (shown as the mean ± the SD). 
(F) Sequence of DNA probes used in EMSAs in G. (G) EMSA using a WT 
probe or probes methylated at the indicated CpGs and nuclear extracts 
from mouse splenic CD4+ T cells expanded with anti-CD3, anti-CD28, 
and IL-2 for 6 d.JEM VOL. 204, July 9, 2007  1549
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DNA methylation of the CpG island inhibits FoxP3 promoter 
activity and CREB binding
The ability of 5-azacytidine and the Dnmt1 shRNA to acti-
vate FoxP3 gene expression could be indirect or direct. We 
thus investigated if DNA methylation of the CpG island 
could inhibit CNS3-mediated reporter activity and CREB 
DNA-binding activity. The +4,301 to +4,500 region was 
either not methylated or was methylated using SssI (CpG) 
methylase and S-adenosylmethionine and inserted into un-
methylated pFoxP3Pro. A transient reporter assay showed an 
almost complete reduction in luciferase activity after methyl-
ation of the intronic CpG island (Fig. 4 E, sixth construct), 
but not with the unmethylated CpG island (fi  fth construct), 
indicating that DNA methylation can directly inhibit its tran-
scriptional activating potential. This is consistent with a direct 
eff  ect of 5-azacytidine and the Dnmt1 shRNA.
We identifi  ed CREB/ATF as a regulator of FoxP3 expres-
sion and provided data that methylation of the CpG island in 
CNS3 can inhibit FoxP3 promoter activity. To directly study 
the eff  ect of DNA methylation on CREB binding activity, 
we performed EMSAs using DNA probes spanning the FoxP3 
+4,473 CREB motifs that were either unmethylated, methyl-
ated only at the +4,473 CpG, or simultaneously methylated at 
the +4,461, +4,466, and +4,473 CpGs (Fig. 4 F). As in Fig. 
1 B, EMSAs performed with the unmethylated oligonucleotide 
probe showed complexes I–IV (Fig. 4 G, lane 1). In contrast, 
the same sequence methylated at only the +4,473 position 
or at all three sites abolished formation of CREB complexes II 
and III, whereas complexes I and IV remained and a new com-
plex appeared (Fig. 4 G, lanes 2 and 3). Thus, methylation of 
the CpG site at +4,473 or all three CpG sites inhibit in vitro 
binding of CREB, but not YY1.
The FoxP3 promoter and CNS3 regions have open 
chromatin structures
We next investigated whether the FoxP3 locus exists in 
an open or closed chromatin conformation using a restric-
tion enzyme accessibility (REA) assay. As compared with 
naive CD4+CD25– T cells, higher REA was observed in 
CD4+CD25+ T cells at both the promoter and CNS3 (Fig. 
5 A) regions, suggesting that an open chromatin structure in 
these regions facilitates transcription of the FoxP3 gene and 
further establishing the importance of CNS3 and CREB/ATF 
in FoxP3 gene regulation. When we examined phospho-
CREB binding in vivo by chromatin immunoprecipitation 
(ChIP) assay, we did not observe binding to the promoter re-
gion in either CD4+CD25– or CD4+CD25+ cells (Fig. 5 B); 
however, in vivo phospho-CREB binding was observed in 
the CNS3 intronic CpG island region, but only in T reg cells 
(Fig. 5 B), which is consistent with the vital role of CREB 
for FoxP3 expression. Having shown that methylation could 
inhibit reporter activity of CNS3, as well as in vitro binding of 
CREB/ATF, we sought to clarify the basis for FoxP3 methyla-
tion, examining the interaction of DNA methyltransferase and 
methyl-CpG–binding proteins at the FoxP3 locus. MeCP2, 
like other methyl-CpG–binding proteins, can bind sequences 
containing methylated cytosines and repress transcription (28). 
Chromatin from CTLL-2 cells that were untreated or treated 
with 5-azacytidine for 3 d was precipitated with antibodies to 
Dnmt1 or MeCP2, and the precipitated DNA was amplifi  ed 
using primer sets for the promoter or CpG island region of the 
FoxP3 gene. This ChIP analysis revealed Dnmt1 and MeCP2 
binding to both the promoter and the intronic CpG island 
(Fig. 5 C) regions in untreated CTLL-2 cells, with a signifi  -
cant reduction after treatment with 5-azacytidine (Fig. 5 C), 
Figure 5.  REA assay with RsaI at the promoter and CNS3 CpG 
island regions of the FoxP3 locus. (A) The data were quantitated 
using a two-step nested real-time PCR strategy and expressed as a 
ratio of digestion at the FoxP3 promoter or CNS3 to digestion at the 
Actin gene locus. (B) ChIP at the promoter and CNS3 CpG island regions 
of the FoxP3 locus revealing phospho-CREB binding only to the CpG 
island region in CD4+CD25+ T reg cells. (C) CTLL-2 cells cultured in the 
presence of 100 U/ml IL-2 for 6 d were incubated with 5-azacytidine 
for the last 3 d, and ChIP assays were performed with preimmune 
serum or antibodies to MeCP2 or Dnmt1. (D) CD4+CD25– cells from 
male C57BL/6 mice isolated by FACS sorting were stimulated with 5 μg/ml 
anti-CD3, 0.5 μg/ml anti-CD28, and 100 U/ml IL-2 in the absence or 
presence of 5 ng/ml TGF-β for 6 d. ChIP assays were performed with 
preimmune serum or antibodies to Dnmt1 or phospho-CREB. Results 
are representative of three or more independent experiments (shown 
as the mean ± the SD).1550  CREB/ATF-DEPENDENT FOXP3 GENE EXPRESSION | Kim and Leonard 
correlating with the lower methylation seen after this treat-
ment. Moreover, when primary mouse CD4+ T cells were 
cultured with anti-CD3, anti-CD28, and IL-2, the addition 
of TGF-β resulted in decreased Dnmt1 binding to the FoxP3 
locus in vivo, as evaluated by ChIP. In contrast, in vivo bind-
ing of phospho-CREB was increased in TGF-β–treated cells 
(Fig. 5 D), again, inversely correlating DNA methylation with 
factor binding in vivo.
Conclusion and model
We found a new TCR response element in the fi  rst intron 
of the FoxP3 gene that is located within a CNS. This CNS con-
tains a CpG island that we have shown is regulated by CREB. 
Epigenetic modifi  cations have been implicated in gene regula-
tion during embryonic development, genomic imprinting, and 
X chromosome inactivation (28). In mammals, epigenetic regu-
lation is mediated by changes in chromatin structure, result  ing 
from either histone modifi  cation or DNA methylation. We 
have shown that DNA methylation can infl  uence long-lasting 
changes in FoxP3 expression during T reg cell development.
Fig. S10 (available at http://www.jem.org/cgi/content/
full/jem.20070109/DC1) shows a model focusing on the 
intronic CNS3 region that integrates the contribution of 
  sequence-specifi  c transcription factors, including CREB (based 
on this study) and Stat5 proteins (19), as well as DNA meth-
ylation in the regulation of the FoxP3 gene. In T reg cells, 
IL-2 and TCR promote the recruitment of Stat5 and CREB, 
thus driving FoxP3 transcription, whereas in non–T reg cells, 
these critical sites are methylated, inhibiting transcription fac-
tor binding, and thus preventing FoxP3 transcription. Over-
all, our studies substantially extend our knowledge of FoxP3 
regulation, with our discovery of a novel CREB-dependent 
TCR response element that is regulated by methylation to 
control expression of a gene that exhibits exquisite lineage-
restricted expression.
MATERIALS AND METHODS
Mice. C57BL/6 mice were obtained from The Jackson Laboratory. All 
experiments were performed under protocols approved by the National Heart, 
Lung, and Blood Institute (NHLBI) Animal Use and Care Committee and 
followed the National Institutes of Health guidelines for Using Animals in 
Intramural Research. CD4+CD25– and CD4+CD25+ T cells were purifi  ed 
from the spleens of C57BL/6 mice by FACS. The purity of each cell popu-
lation was >98%.
Antibodies, cell staining, and fl  ow  cytometry. Conjugated anti-
bodies were purchased from BD Biosciences and eBioscience. A FACSort 
(Becton Dickinson) was used for fl  ow cytometry, and data were analyzed 
with FlowJo software. For intracellular FoxP3 fl  ow cytometry, cells were 
stained using a standard protocol according to the manufacturer’s instruc-
tions (eBioscience).
Plasmid constructs. The −500 to +100 region of the FoxP3 gene was 
PCR amplifi   ed and cloned into pGL3-Basic to yield pFoxP3pro. The 
+2,022 to +2,721 and +4,001 to +4,820 regions were PCR amplifi  ed and 
inserted into pFoxP3pro to yield pFoxP3pro/CNS2 and pFoxP3pro/CNS3. 
The CpG region between +4,301 and +4,500 was similarly inserted into 
FoxP3Pro to yield FoxP3Pro/CpGisl. The QuikChange Site-Directed 
  Mutagenesis kit (Stratagene) was used to mutate the CREB site (+4,473) in 
FoxP3Pro/CpGisl. The dominant-negative CREB construct (ACREB) was 
provided by J.-M. Park (Harvard Medical School, Boston, MA) and sub-
cloned into pLentilox RSV vector, which has a puromycin marker. The 
plasmids encoding shRNA against Dnmt1 were provided by T. Jacks (Mas-
sachussetts Insitute of Technology, Cambridge, MA) (29).
Lentiviral transduction. 293T cells (8 × 106) were seeded onto 150-mm 
dishes, and 16 h later they were transiently transfected with 1 μg of lentiviral 
vector and 3 μg of each packaging vector (Invitrogen) by using Eff  ectene 
(QIAGEN). Supernatants were collected 48 h after transfection, fi  ltered 
through a 0.45-μM fi  lter, and centrifuged at 25,000 rpm for 2 h. The viral 
pellet was resuspended in RPMI medium. MT-2 or CTLL-2 cells (106) 
were seeded into 24-well plates, and 6 μg/ml of polybrene and virus were 
added at a 5:1 (virus/cell) multiplicity of infection. Cells were spin infected 
for 90 min at 2,500 rpm and cultured at 37°C.
Transient transfections and luciferase assays. Jurkat cells were tran-
siently transfected using DEAE-dextran. Transient transfections of normal 
mouse T cells were performed by electroporation (30).
EMSA. EMSAs were performed as previously described (16). For super-
shifting assays, nuclear extracts were preincubated for 10 min with CREB 
and phospho-CREB (Millipore). The oligonucleotide probes are shown in 
the Supplemental materials and methods (available at http://www.jem.org/
cgi/content/full/jem.20070109/DC1) and in Fig. 4 F.
Quantitative RT-PCR. Total RNA was isolated from cells using RNeasy 
(QIAGEN). First-strand cDNAs were made using the Omniscript RT kit 
(QIAGEN). Quantitative real-time PCR was performed on a 7900H se-
quence detection system (Applied Biosystems). TaqMan Gene Expression 
Assays (Applied Biosystems) were used to measure the mRNA levels of 
human FOXP3, human IL-2Rα, human GAPDH, mouse Dnmt1, mouse 
Dnmt3a, and mouse FOXP3.
Methylation analysis. Genomic DNA was purifi  ed with the Wizard ge-
nomic DNA purifi  cation kit (Promega). Methylation analysis was performed 
by bisulfi  te conversion of genomic DNA using the MethylDetector kit 
(Active Motif). The primer sequences to amplify the FoxP3 promoter region 
and the FoxP3 CpG island region are listed in the Supplemental materials 
and methods. The PCR product was cloned using the TOPO TA Cloning 
kit (Invitrogen).
Plasmid methylation. For plasmid methylation, the +4,301 to +4,500 
CpG island region was amplifi  ed by PCR, and 5 μg of PCR product was 
incubated with 80 U of SssI methylase and 640 μM S-adenosylmethionine 
(New England Biolabs) for 2 h at 37°C. DNA methylation was verifi  ed using 
AatII, which is a methylation-sensitive restriction enzyme. The pGL3-Basic 
vector containing the FoxP3 promoter region was cut with KpnI and SacI 
and ligated with an equimolar concentration of the methylated or unmethyl-
ated CpG island region at 16°C for 2 h. DNA was purifi  ed using the Qia-
Quick method (QIAGEN), and 4 μg of ligated DNA was transfected into 
Jurkat cells using DEAE-Dextran.
REA assay. REA assays were performed as previously described (17). The 
sequences of primers and probes used for the PCR are listed in the Supple-
mental materials and methods.
ChIP. ChIP assays were performed as previously described (17). The prim-
ers and Taqman probe sequences for the FoxP3 promoter and the intronic 
CpG island are listed in the Supplemental materials and methods.
Online supplemental material. Fig. S1 shows the delineation of CNS3 
region as a TCR response element. Fig. S2 shows the sequence of the pro-
moter and CNS3. Fig. S3 shows sequence of the EMSA probes. Fig. S4 
shows that complex I contains YY1. Fig. S5 shows a summary of the data in JEM VOL. 204, July 9, 2007  1551
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Fig. 2 (C–F). Fig. S6 shows the DNA methylation status of CpG sites in 
the promoter and intronic CpG island region of the FoxP3 gene in thymo-
cytes. Fig. S7 shows the DNA methylation status of CpG sites in the IL-2 
and IFN-γ genes. Fig. S8 shows the summary of the data in Fig. 3 (B, C, E, 
and F). Fig. S9 shows that treatment with 5-azacytidine stimulates FoxP3 
expression in CTLL-2 cells. Fig. S10 shows the schematic of FoxP3 gene 
regulation in T reg and non–T reg cells. The Supplemental materials and 
methods show the sequence of primer and probe used in the experiment. 
The online version of this article is available at http://www.jem.org/cgi/
content/full/jem.20070109/DC1.
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